Current evidence of epidermal barrier dysfunction and thymic stromal lymphopoietin in the atopic march

European Respiratory Review

Volumn 23, Issue 133, 2014, Pages 292-298

  Li, Mei ^a,b,c  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; THYMIC STROMAL LYMPHOPOIETIN;

ANIMAL; BIOSYNTHESIS; CORNEA CELL; EPIDERMIS; HUMAN; HYPERSENSITIVITY; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CORNEAL KERATOCYTES; CYTOKINES; EPIDERMIS; HUMANS; HYPERSENSITIVITY; MICE;

EID: 84906877097     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004314     Document Type: Review

References (65)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
2. Ober C, Yao T-C. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 2011; 242: 10-30.
3. Hahn EL, Bacharier LB. The atopic march: the pattern of allergic disease development in childhood. Immunol Allergy Clin North Am 2005; 25: 231-246.
4. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657.
5. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105: 99-106.
6. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: Suppl. 6, S118-S127.
7. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-246.
8. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis - a prospective follow-up to 7 years of age. Allergy 2000; 55: 240-245.
9. Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999; 104: 1280-1284.
10. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001; 107: 429-440.
11. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012; 67: 1475-1482.
12. Benedetto AD, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? J Invest Dermatol 2012; 132: 949-963.
13. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest 2012; 122: 440-447.
14. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141-142.
15. Kato A, Fukai K, Oiso N, et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665-669.
16. Nishio Y, Noguchi E, Shibasaki M, et al. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun 2003; 4: 515-517.
17. Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001; 29: 175-148.
18. Kusunoki T, Okafuji I, Yoshioka T, et al. SPINK5 polymorphism is associated with disease severity and food allergy in children with atopic dermatitis. J Allergy Clin Immunol 2005; 115: 636-638.
19. Hubiche T, Ged C, Benard A, et al. Analysis of SPINK 5, KLK7 and FLG genotypes in a French atopic dermatitis cohort. Acta Derm Venereol 2007; 87: 499-505.
20. Israeli S, Zamir H, Sarig O, et al. Inflammatory peeling skin syndrome caused by a mutation in CDSN encoding corneodesmosin. J Invest Dermatol 2011; 131: 779-781.
21. Oji V, Eckl K-M, Aufenvenne K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010; 87: 274-281.
22. Kezic S, Kemperman PM, Koster ES, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008; 128: 2117-2119.
23. O'Regan GM, Sandilands A, McLean WH, et al. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008; 122: 689-693.
24. Smith FJD, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38: 337-342.
25. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
26. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009; 339: b2433.
27. Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a populationbased, longitudinal birth cohort study. J Allergy Clin Immunol 2008; 121: 872-877.
28. Weidinger S, O'Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121: 1203-1209.
29. Marenholz I, Bauerfeind A, Esparza-Gordillo J, et al. The eczema risk variant on chromosome 11q13 (rs7927894) in the population-based ALSPAC cohort: a novel susceptibility factor for asthma and hay fever. Hum Mol Genet 2011; 20: 2443-2449.
30. Brown SJ, Relton CL, Liao H, et al. Filaggrin null mutations and childhood atopic eczema: a population-based casecontrol study. J Allergy Clin Immunol 2008; 121: 940-946.
31. Schuttelaar ML, Kerkhof M, Jonkman MF, et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy 2009; 64: 1758-1765.
32. Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011; 127: 661-667.
33. Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45: 1244-1248.
34. Klar J, Schweiger M, Zimmerman R, et al. Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome. Am J Hum Genet 2009; 85: 248-253.
35. Sevilla LM, Nachat R, Groot KR, et al. Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier. J Cell Biol 2007; 179: 1599-1612.
36. Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest 2006; 116: 1150-1158.
37. Li M, Indra AK, Warot X, et al. Skin abnormalities generated by temporally controlled RXRa mutations in mouse epidermis. Nature 2000; 407: 633-636.
38. Metzger D, Li M, Chambon P. Targeted somatic mutagenesis in the mouse epidermis. Methods Mol Biol 2005; 289: 329-340.
39. Herrick CA, MacLeod H, Glusac E, et al. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 2000; 105: 765-775.
40. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 1998; 28: 769-779.
41. Oyoshi MK, Murphy GF, Geha RS. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 2009; 124: 485-493.
42. Spergel JM, Mizoguchi E, Brewer JP, et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101: 1614-1622.
43. Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004; 34: 2100-2109.
44. Wang G, Savinko T, Wolff H, et al. Repeated epicutaneous exposures to ovalbumin progressively induce atopic dermatitis-like skin lesions in mice. Clin Exp Allergy 2007; 37: 151-161.
45. Leyva-Castillo JM, Hener P, Jiang H, et al. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol 2013; 133: 154-163.
46. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol 2012; 130: 845-852.
47. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-680.
48. Lee EB, Kim KW, Hong JY, et al. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol 2010; 21: e457-e460.
49. Yao W, Zhang Y, Jabeen R, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity 2013; 38: 360-372.
50. Alysandratos KD, Angelidou A, Vasiadi M, et al. Increased affected skin gene expression and serum levels of thymic stromal lymphopoietin in atopic dermatitis. Ann Allergy Asthma Immunol 2010; 105: 403-404.
51. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013; 351: 289-300.
52. Li M, Messaddeq N, Teletin M, et al. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci USA 2005; 102: 14795-14800.
53. Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005; 202: 541-549.
54. Li M, Hener P, Zhang Z, et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 2006; 103: 11736-11741.
55. Zhang Z, Hener P, Frossard N, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci USA 2009; 106: 1536-1541.
56. Demehri S, Morimoto M, Holtzman MJ, et al. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol 2009; 7: e1000067.
57. Takeda K, Gelfand EW. Mouse models of allergic diseases. Curr Opin Immunol 2009; 21: 660-665.
58. Holgate S. Perspective: a human touch. Nature 2011; 479: S22.
59. Oyoshi MK, Larson RP, Ziegler SF, et al. Mechanical injury polarizes skin dendritic cells to elicit a Th2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol 2010; 126: 976-984.
60. Angelova-Fischer I, Fernandez IM, Donnadieu M-H, et al. Injury to the stratum corneum induces in vivo expression of human thymic stromal lymphopoietin in the epidermis. J Invest Dermatol 2010; 130: 2505-2507.
61. Li M, Hener P, Zhang Z, et al. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J Invest Dermatol 2009; 129: 498-502.
62. Jiang H, Hener P, Li J, et al. Skin thymic stromal lymphopoietin promotes airway sensitization to inhalant house dust mites leading to allergic asthma in mice. Allergy 2012; 67: 1078-1082.
63. Platts-Mills TA, de Weck AL. Dust mite allergens and asthma - a worldwide problem. J Allergy Clin Immunol 1989; 83: 416-427.
64. Noti M, Wojno EDT, Kim BS, et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nature Med 2013; 19: 1005-1013.
65. Noti M, Kim BS, Siracusa MC, et al. Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. J Allergy Clin Immunol 2014; 133: 1390-1399.